These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 38216224)
1. Development of Mobile Contingency Management for Cannabis Use Reduction. Beckham JC; Calhoun PS; Chen Z; Dennis MF; Kirby AC; Treis ET; Hertzberg JS; Hair LP; Mann AJ; Budney AJ; Kimbrel NA Behav Ther; 2024 Jan; 55(1):1-13. PubMed ID: 38216224 [TBL] [Abstract][Full Text] [Related]
2. Contingency management is associated with positive changes in attitudes and reductions in cannabis use even after discontinuation of incentives among non-treatment seeking youth. Cooke ME; Knoll SJ; Streck JM; Potter K; Lamberth E; Rychik N; Gilman JM; Evins AE; Schuster RM Drug Alcohol Depend; 2024 Mar; 256():111096. PubMed ID: 38277735 [TBL] [Abstract][Full Text] [Related]
3. A contingency management intervention to reduce cannabis use and time to relapse in early psychosis: the CIRCLE RCT. Johnson S; Rains LS; Marwaha S; Strang J; Craig T; Weaver T; McCrone P; King M; Fowler D; Pilling S; Marston L; Omar RZ; Craig M; Spencer J; Hinton M Health Technol Assess; 2019 Aug; 23(45):1-108. PubMed ID: 31460865 [TBL] [Abstract][Full Text] [Related]
4. A contingency management method for 30-days abstinence in non-treatment seeking young adult cannabis users. Schuster RM; Hanly A; Gilman J; Budney A; Vandrey R; Evins AE Drug Alcohol Depend; 2016 Oct; 167():199-206. PubMed ID: 27590742 [TBL] [Abstract][Full Text] [Related]
5. A Web-Based Self-Help Intervention With and Without Chat Counseling to Reduce Cannabis Use in Problematic Cannabis Users: Three-Arm Randomized Controlled Trial. Schaub MP; Wenger A; Berg O; Beck T; Stark L; Buehler E; Haug S J Med Internet Res; 2015 Oct; 17(10):e232. PubMed ID: 26462848 [TBL] [Abstract][Full Text] [Related]
6. Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder. Tomko RL; Baker NL; Hood CO; Gilmore AK; McClure EA; Squeglia LM; McRae-Clark AL; Sonne SC; Gray KM Psychopharmacology (Berl); 2020 Feb; 237(2):479-490. PubMed ID: 31712969 [TBL] [Abstract][Full Text] [Related]
7. Evaluating cannabis use risk reduction as an alternative clinical outcome for cannabis use disorder. Sherman BJ; Sofis MJ; Borodovsky JT; Gray KM; McRae-Clark AL; Budney AJ Psychol Addict Behav; 2022 Aug; 36(5):505-514. PubMed ID: 34197135 [TBL] [Abstract][Full Text] [Related]
8. Alcohol substitution during one month of cannabis abstinence among non-treatment seeking youth. Schuster RM; Potter K; Lamberth E; Rychik N; Hareli M; Allen S; Broos HC; Mustoe A; Gilman JM; Pachas G; Evins AE Prog Neuropsychopharmacol Biol Psychiatry; 2021 Apr; 107():110205. PubMed ID: 33309538 [TBL] [Abstract][Full Text] [Related]
9. A method to achieve extended cannabis abstinence in cannabis dependent patients with schizophrenia and non-psychiatric controls. Rabin RA; Kozak K; Zakzanis KK; Remington G; Stefan C; Budney AJ; George TP Schizophr Res; 2018 Apr; 194():47-54. PubMed ID: 28506704 [TBL] [Abstract][Full Text] [Related]
10. Cannabis Use in Adults Who Screen Positive for Attention Deficit/Hyperactivity Disorder: CANreduce 2.0 Randomized Controlled Trial Subgroup Analysis. Ahlers J; Baumgartner C; Augsburger M; Wenger A; Malischnig D; Boumparis N; Berger T; Stark L; Ebert DD; Haug S; Schaub MP J Med Internet Res; 2022 Apr; 24(4):e30138. PubMed ID: 35442196 [TBL] [Abstract][Full Text] [Related]
11. Abstinence and reduced frequency of use are associated with improvements in quality of life among treatment-seekers with cannabis use disorder. Brezing CA; Choi CJ; Pavlicova M; Brooks D; Mahony AL; Mariani JJ; Levin FR Am J Addict; 2018 Mar; 27(2):101-107. PubMed ID: 29457671 [TBL] [Abstract][Full Text] [Related]
12. A preliminary randomized controlled trial of repetitive transcranial magnetic stimulation applied to the left dorsolateral prefrontal cortex in treatment seeking participants with cannabis use disorder. Sahlem GL; Kim B; Baker NL; Wong BL; Caruso MA; Campbell LA; Kaloani I; Sherman BJ; Ford TJ; Musleh AH; Kim JP; Williams NR; Manett AJ; Kratter IH; Short EB; Killeen TK; George MS; McRae-Clark AL Drug Alcohol Depend; 2024 Jan; 254():111035. PubMed ID: 38043228 [TBL] [Abstract][Full Text] [Related]
13. Reducing Cannabis Use in Young Adults With Psychosis Using iCanChange, a Mobile Health App: Protocol for a Pilot Randomized Controlled Trial (ReCAP-iCC). Tatar O; Abdel-Baki A; Wittevrongel A; Lecomte T; Copeland J; Lachance-Touchette P; Coronado-Montoya S; Côté J; Crockford D; Dubreucq S; L'Heureux S; Ouellet-Plamondon C; Roy MA; Tibbo PG; Villeneuve M; Jutras-Aswad D JMIR Res Protoc; 2022 Nov; 11(11):e40817. PubMed ID: 36427227 [TBL] [Abstract][Full Text] [Related]
14. Mobile contingency management as an adjunctive treatment for co-morbid cannabis use disorder and cigarette smoking. Beckham JC; Adkisson KA; Hertzberg J; Kimbrel NA; Budney AJ; Stephens RS; Moore SD; Calhoun PS Addict Behav; 2018 Apr; 79():86-92. PubMed ID: 29268146 [TBL] [Abstract][Full Text] [Related]
15. Cannabis Use Disorder Treatment Preferences: A Pilot Survey in Current Users of Cannabis. Lile JA; Turner BW; Cox DH; Bonn-Miller MO; Katz NR; Shellenberg TP; Stoops WW; Strickland JC J Addict Med; 2023 Mar-Apr 01; 17(2):e87-e93. PubMed ID: 36731101 [TBL] [Abstract][Full Text] [Related]
16. Reduction in Cannabis Use and Functional Status in Physical Health, Mental Health, and Cognition. Mooney LJ; Zhu Y; Yoo C; Valdez J; Moino K; Liao JY; Hser YI J Neuroimmune Pharmacol; 2018 Dec; 13(4):479-487. PubMed ID: 30284156 [TBL] [Abstract][Full Text] [Related]
17. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
18. Biological correlates of self-reported new and continued abstinence in cannabis cessation treatment clinical trials. Baker NL; Gray KM; Sherman BJ; Morella K; Sahlem GL; Wagner AM; McRae-Clark AL Drug Alcohol Depend; 2018 Jun; 187():270-277. PubMed ID: 29698894 [TBL] [Abstract][Full Text] [Related]
19. Characterizing cannabis use reduction and change in functioning during treatment: Initial steps on the path to new clinical endpoints. Borodovsky JT; Sofis MJ; Sherman BJ; Gray KM; Budney AJ Psychol Addict Behav; 2022 Aug; 36(5):515-525. PubMed ID: 35084903 [TBL] [Abstract][Full Text] [Related]
20. Smartphone-based ecological momentary assessment (EMA) of alcohol and cannabis use in older adults with and without HIV infection. Paolillo EW; Obermeit LC; Tang B; Depp CA; Vaida F; Moore DJ; Moore RC Addict Behav; 2018 Aug; 83():102-108. PubMed ID: 29126667 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]